ICYMI: Webinar Highlights How Introduction of More Biosimilars to U.S. Market Will Encourage Competition and Lower Prescription Drug Costs
New Paper Finds Potential Cost Savings from Adalimumab Biosimilars are Significant but Competitive Market Will Take Time The Pharmaceutical Care Management Association (PCMA) agrees that biosimilars bring more competition to the prescription drug marketplace, which is critical to lowering costs